The 483 is already a search.

FDA work lives in the gap between what the company believes it has done and what the agency will accept: observations, a stalled submission, a quality system that will not hold. Referrals still come from a GC who watched a prior salvage. That pool has edges. Quality and regulatory already looking do not wait for that pool.

Writing to quality directors is the outbound program. It is not this page. We do not write into the warning letter. The job is to be findable in the days the observation or the submission is already a search, and to be the name referring counsel already has when the last three shops are the wrong three.

Healthcare regulatory and HIPAA are different leaves on regulatory compliance.

How These Deals Actually Work

The gap shows up as a 483 observation after an inspection, a submission that has stalled at the agency, or a quality system that will not hold up if inspected again. None of these are theoretical. The company already has a specific document, a specific citation, or a specific stalled file in hand, and quality and regulatory leadership are now on a clock to respond credibly before it becomes a warning letter or worse.

A GC who watched a prior salvage is a real referral source, but that pool has hard edges: most GCs have only seen this once or twice in their career, and the quality director staring at a fresh 483 this week is not waiting for that GC to remember a name from a different company years ago.

Healthcare regulatory compliance and HIPAA are different leaves entirely on regulatory compliance. FDA observations and submissions are a distinct regulator, a distinct clock, and a distinct buyer from hospital survey citations or patient-data risk analyses.

What a Buyer Is Actually Searching

The quality or regulatory director with a fresh observation searches specifically: 483 response consultant, FDA warning letter consultant, quality system remediation. They have a document in hand and a deadline attached to it.

A regulatory affairs lead with a stalled submission searches differently: FDA submission consultant, 510k consultant, regulatory strategy consulting. The urgency is commercial, a delayed launch, not enforcement.

A generic "FDA consultant" campaign misses the difference between a company responding to an observation this week and one trying to get a submission unstuck months from now.

Objections We Hear

Our regulatory affairs team handles this internally. Internal teams often lack observation-response or submission-remediation experience specifically, because most companies see a serious 483 rarely enough that nobody in-house has done it more than once.

Outside counsel is already advising us. Counsel manages legal exposure. The technical response, closing the quality-system gaps the observation identified, is a different, more operational deliverable.

We will wait and see if it escalates. A weak 483 response is exactly what turns an observation into a warning letter. Waiting is the risk, not a strategy.

Who This Is Actually For

Firms that actually remediate quality systems and respond to observations, in the product categories they know, with the capacity to turn around a response inside the agency's timeline. The lead worth the spend is a company with a real observation or a genuinely stalled submission.

This is a poor fit for a firm whose real strength is regulatory strategy for new products with no active enforcement issue, or one without the technical staff to actually close quality-system gaps. Bid the observation and remediation work you actually run.

Ready to grow your pipeline?

Share a few details and we'll follow up with exactly how this works for a firm like yours.

Leave blank

Name *

Firm / Company *

Email *

Phone

Send

How the campaign runs

Google ads for the people already looking. Not one generic “FDA consultant” campaign. Quality and regulatory leads searching an observation, a submission, or a quality-system gap, in the product types you actually work. Keywords are always custom to the work you do. Brand bidding and competitor-brand bidding only when the strategy calls for it. Details: paid search.

Foundational work in parallel: the website, local directories, and general search appearance, so the click lands on an FDA shop and not a volume mill. Bios and listings in the language of the observation and the system. A landing page may be included; a full website is quoted separately. Directories and bios: online profile development.

LinkedIn ads aimed at referring counsel: lunch-and-learns for FDA and life-sciences lawyers who send the file after they already know three shops. Paid ads only. We do not offer LinkedIn message outreach (InMail, connection sequences, or DMs). That is a different channel, we do not run it, and it is not part of this program.

Ads produce inbound while the search is live. Foundation is why a quality lead, a regulatory VP, or a referring lawyer trusts the shop enough to call.

Why we're not generalists

Generalist marketing agencies will not take the time to understand how this practice actually wins work. The practice is too specialized, the file count is too small, and the work of understanding it bores them. They want large spend and a lot of traffic to a landing page. We will run a tight campaign for a shop that closes fewer files at a higher value. That is the point of this page.

Most agencies do not understand specialized industries well enough to advertise them honestly. We take the time to learn how the work is sold so the keywords and the page the click lands on match the work you actually take. A complex practice deserves that. A generic landing page does not.

How fast this can run

We can get ads live in under a week. What usually slows that down is approval on your side: the keywords, the spend, the page the click lands on. Directories, bios, and a site a buyer will trust take longer to finish. The website and listings are why the person who clicks trusts you. It is not the same as going live on search.

How this is billed

This is Visibility Program work, not the outbound program. You pay ad spend directly to the platforms (Google and, where we run it, LinkedIn). ROI Wire is billed on a retainer that scales with that spend. That is not a flat project fee, not a percentage of closed files, and not an outbound retainer.

A landing page may be included at no additional cost. A full website build is always quoted and billed separately. Foundational services (copywriting, CRM, multichannel sequences, web design) sit under this track as the credibility layer, not as a correspondence program.

Scope is on the Visibility Program. Search mechanics are on paid search. Surfaces are on online profile development.

What is not included

We do not build a solicitation list of quality or regulatory executives. We do not write, mail, or phone companies who did not ask. We do not sit the 483, file the submission, or run the quality system. We make the shop findable. The shop does the work.

This is not healthcare regulatory and not HIPAA. Those are different pages.

Program pages

Visibility Program

How this work is scoped and billed.

Paid search

Google ads. You pay the ad spend. We bill a retainer that scales with it.

Online profile development

Directories, bios, and reputation surfaces a buyer checks after they see you.